-
Health todayObesity, diabetes and GLP-1 new
Adults with diabetes lost more muscle after starting a GLP-1 drug
In the German National Cohort, adults with diabetes who started a GLP-1 drug lost 2.75 percentage points more skeletal muscle volume than matched adults who did not.
Preprint · not peer-reviewed -
Health todayHeart and stroke new
The largest treatment gaps are not where cardiovascular risk could fall most
The populations with the largest treatment gaps were not those where treating currently untreated people would achieve the greatest absolute reduction in cardiovascular risk.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Diabetes was more common in older US influenza deaths than in COVID-19 deaths
Among US inpatients aged over 65 who died, 46.6% of those dying of COVID-19 had diabetes, as compared to 63.1% of those dying of influenza.
Peer-reviewed -
Health todayCancer refines
Pancreatic cancer risk on GLP-1 drugs depends on the diabetes drug compared
Pancreatic cancer was less common in GLP-1 starters than in starters of four other diabetes classes, while against insulin the paper reports a lower hazard but a higher absolute risk.
Peer-reviewed -
Health todayCancer confirms
Colorectal screening from 45 still misses cancers diagnosed before that age
A review of 45 studies found detection of colorectal neoplasia rises with age under 50, but a considerable share of cases arise before 45 and outside screening eligibility.
Peer-reviewed -
Health todayHeart and stroke confirms
Cardiogenic shock deaths fall as hospital cardiac capability rises in US admissions
Across an estimated 1.18 million US admissions for cardiogenic shock, crude in-hospital mortality fell from 64.4% at hospitals without percutaneous coronary intervention to 36.5% at heart transplant centres.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
GLP-1 drugs cut weight by 6.7 kg in patients taking antipsychotics
A meta-analysis of eight randomised trials in 664 patients taking antipsychotics found that GLP-1 receptor agonists reduced body weight by 6.74 kg, alongside more nausea, vomiting and constipation.
Peer-reviewed -
Health todayCancer new
Second primary lung cancers in Sweden have risen steadily since 1980
The Swedish national cancer registry identified 853 second primary lung cancers from 1961 to 2021, arising at 3.59 times the rate at which first lung cancers arise in the population.
Peer-reviewed -
Health todayCancer confirms
Scotland's lung screening pilot drew a 23.8% response to its invitations
Inviting 2801 people with a smoking history recorded in Scottish primary care records to a lung health check produced a response rate of 23.8%, lower in more deprived areas.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
GLP-1 drugs did not reduce new sleep apnoea diagnoses in UK diabetes patients
Among UK adults with type 2 diabetes and obesity, those starting a GLP-1 drug rather than a weight-neutral DPP-4 inhibitor had no fewer new sleep apnoea diagnoses (hazard ratio 1.07).
Peer-reviewed -
Health todayCancer new
Oral KRAS G12D inhibitor GFH375 shrank tumours in a third of pancreatic cancers
In 74 heavily pretreated patients with KRAS G12D-mutant advanced solid tumours, the oral inhibitor GFH375 produced confirmed responses in 35.1% of pancreatic cancers and 35.7% of lung cancers.
Peer-reviewed -
Health todayDementia new
Most dementia trial participants had more than one brain pathology at autopsy
Among 67 autopsied participants in dementia trials at a Kentucky research centre, only 10 to 29% had solely the pathology that the trial's intervention was designed to target.
Peer-reviewed
